Recent News for ORMP - Oramed Pharmaceuticals Inc.

Date Title
Oct 17 Oramed Pharmaceuticals And ORMD-0901
Sep 20 We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Needs To Drive Business Growth Carefully
Sep 18 Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
Sep 17 Oramed nearing finish line in mid-stage study of oral insulin
Sep 17 Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
Sep 11 Benzinga's Top Upgrades, Downgrades For September 11, 2019
Sep 11 Goldman likes Bicycle Therapeutics in premarket analyst action
Sep 3 Oramed to Present at Three Upcoming Conferences
Aug 16 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Insiders Increased Their Holdings
Jul 24 7 Stocks on Sale the Insiders Are Buying
Jul 12 Key events next week - healthcare
Jul 11 What Kind Of Investor Owns Most Of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)?
Jul 10 Oramed to Present at World Diabetes Congress
Jul 2 Amarin and Celyad among healthcare gainers; CEL-SCI and Oramed Pharmaceuticals among losers
Jul 2 Oramed Announces Xiaoming Gao Joins Board of Directors
Jun 25 ORMP: Phase 2b Trial of ORMD-0801 Fully Enrolled; Data Expected 4Q19…
Jun 18 Oramed Provides Clinical Update with Meaningful Data Expected by Year-End
Jun 3 Oramed to Present at BIO International Convention
May 21 Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801
May 7 ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19…
Apr 29 Oramed to Present at ThinkEquity Conference
Apr 28 Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Slid 60% In The Last Five Years
Back to the Main ORMP Page...